TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04998162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF injection
Description: Patients with ankle osteoarthritis will be treated with a single injection of 5 cc of SVF (stromal vascular fraction), obtained from patient's abdominal adipose tissue and concentrated through OPTYFAT device. Infiltration of the ankle, occurs from the safest portal, that is, from the antero- medial, between the tibialis anterior and the saphenous vein and nerve at the level of the articular rima.
Study: NCT06175039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program
Description: TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone.

Intervention type: OTHER
Group type: OTHER
Intervention: Control program
Description: KGr will be a pulmonary rehabilitation information brochure will be given after the initial evaluation. They will be asked to do the exercises on the brochure.
Study: NCT05873270

Intervention type: OTHER
Intervention: Wrist and ankle acupuncture
Description: Patients in the intervention arm started the wrist and ankle acupuncture treatment 1 day before the surgery. Take up and down 1,2 area as a needle point, use hua tuo brand sterile acupuncture needle (specification: 0.25mm 25mm), into the skin disinfection into the needle, keep 30 subcutaneous needle and skin, when the operator under the needle, patients without acid swelling, pain, close to the skin dermis, to about 1.5 inches, give tape fixed 24h, left under the skin, until postoperative 3 day.
Study: NCT06352866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab is an investigational (experimental) drug that works by binding directly to human interleukin-6 (IL-6). IL-6 is a cytokine; these are products that are secreted by certain cells of the immune system and effect other cells in participant's body. IL-6 regulates immune, inflammatory and metabolic processes. Siltuximab has already been tested and approved for use by the FDA in participants with a condition called multicentric Castleman's disease, which is a disorder of the lymphatic system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab(FDA-approved)
Description: Teclistamab is a FDA-approved drug for the treatment of advanced MM after 4 lines of therapy.
Study: NCT05323877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Device (PerQseal+)
Description: Percutaneous arterial closure device
Study: NCT05928039

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNFa Antagonist - Infliximab
Description: • Infliximab 5 mg/kg intravenously \[IV\] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNFa Antagonist - Adalimumab
Description: • Adalimumab subcutaneously \[SC\] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-IL12/23 or anti-IL23 - Ustekinumab
Description: • Ustekinumab \~6 mg/kg IV x1, then 90 mg SC every 8 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-IL12/23 or anti-IL23 - Risankizumab
Description: • Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-integrin - Vedolizumab IV
Description: • Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-integrin - Vedolizumab IV and SC
Description: • Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
Study: NCT05477004

Intervention type: DRUG
Intervention: Ketamine
Description: A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
Study: NCT05238688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA) group
Description: Under full aseptic conditions while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine an 18-G Tuohy needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal . After negative response, 15 ml of 0.25% epidural bupivacine will be injected and the patient will be turned to the supine position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group
Description: Thoracic Epidural Analgesia will be done at first. Then, the ultrasound probe will be placed longitudinally 2-3 cm lateral to the T2 spinous process in the sagittal line. The T2 spinous process will be identified by counting down anatomically from the vertebral prominens (C7), and the T2 transverse process will be visualized by counting down from the first rib via real-time ultrasound guidance. The erector spinae muscle will be visualized above the T2 transverse process. The needle will be inserted in a caudal cranial direction using the in-plane technique. A dose of 5 mL normal saline will be injected into the inter-fascial area between the erector spinae muscle and the transverse process for the correction of the injection site (hydro-dissection). After hydro-dissection, 15 mL of 0.25% bupivacaine will be injected here, and the linear spread of the solution will be visualized in the inter-fascial plane.
Study: NCT05555277

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: The differences between the two diagnoses were investigated by using the scale results and EEG data in the patient files.
Study: NCT06282315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomization
Description: Only when the screening process is finalized in a particular school, and the list of eligible participants is closed, with at least 100 eligible participants, will the school be a candidate for randomization. Once the screening process is finalized, the investigator or designee will notify the ISGlobal Trial Statistician, who will provide the School Randomization ID allocated based on the randomization lists created before the trial starts. School Randomization ID will be assigned sequentially per site, following the order of school randomization. Additionally, the ISGlobal Trial Statistician will provide the site with the list of eligible participants per school randomly selected to participate in the Effectiveness Cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization
Description: Only when the screening process is finalized in a particular school, and the list of eligible participants is closed, with at least 100 eligible participants, will the school be a candidate for randomization. Once the screening process is finalized, the investigator or designee will notify the ISGlobal Trial Statistician, who will provide the School Randomization ID allocated based on the randomization lists created before the trial starts. School Randomization ID will be assigned sequentially per site, following the order of school randomization. Additionally, the ISGlobal Trial Statistician will provide the site with the list of eligible participants per school randomly selected to participate in the Effectiveness Cohort.
Study: NCT05789056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRX003, 4% Lotion
Description: QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRX003, 4% Lotion
Description: QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Study: NCT04993209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 1μg
Description: NDV-HXP-S 1μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 3μg
Description: NDV-HXP-S 3μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 10μg
Description: NDV-HXP-S 10μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed inactivated COVID-19 vaccine (CoronaVac)
Description: Adsorbed inactivated COVID-19 vaccine 600 SU/0.5 mL 2 doses intramuscular (deltoid) 28 days apart
Study: NCT05152147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally (PO bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally (PO bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally (PO bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered IV
Study: NCT06650410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Intervention for Vertebral Fractures (VIVA)
Description: VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. An exercise professional leads 1:1 once-weekly sessions (in person or virtual) over eight weeks. Sessions start with brief education on a topic, followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. The exercise professional prescribes resources using an app or that can be emailed or mailed. Exercises are tailored to the participant's abilities, and target balance, muscle strength, and endurance of back extensor muscles and scapular stabilizers.

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Intervention for Vertebral Fractures (VIVA)
Description: VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. An exercise professional leads 1:1 once-weekly sessions (in person or virtual) over eight weeks. Sessions start with brief education on a topic, followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. The exercise professional prescribes resources using an app or that can be emailed or mailed. Exercises are tailored to the participant's abilities, and target balance, muscle strength, and endurance of back extensor muscles and scapular stabilizers.
Study: NCT06652789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions in local language will focus on health education about sleep. (After taking consent)~1. st session (60 mins) Information will be given about lifestyles that can affect sleep positively or negatively- adequate sleep time required for health, healthy and unhealthy sleep habits~2. nd session Participants will be asked to indicate how many of the sleep hygiene techniques they were able to successfully implement since the previous session Successes and barriers will be discussed. provide solutions for standard difficulties faced Twice a week telephone calls. The participants will be followed up through telephonic conversation twice weekly with a gap of three to four days in between each call.
Study: NCT06652802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.
Description: * An interactive mobile based application will be developed with the following features to assist in monitoring and preventing relapse.~* Purpose of the Mobile based application: The mobile application will be an interactive tool designed to assist in monitoring and preventing relapse of alcohol use disorder. It will provide various features to support users in their journey to sobriety, including personalized recovery plans, goal setting, progress tracking, stress and craving management tools, educational resources, daily reflection prompts, emergency assistance, personalized reminders, progress reports, and psychoeducational videos.~* The Target population: 40 Male patients selected through randomized sampling, aged between 18 and 59 years, who have participated in Nurse-Conducted Brief Intervention (NCBI) for AUD in the Gastroenterology ward with diagnosis of alcohol dependence use disorder based on ICD-10 who have access to smartphone application and have the ability to use it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-Conducted Brief Intervention (NCBI)
Description: * Nurse-Conducted Brief Intervention (NCBI) is a feasible and acceptable model of care for males diagnosed with Alcohol Use Disorders (AUDs) in gastroenterology settings. The study found that the Nurse-Conducted Brief Intervention (NCBI) had a positive impact on promoting abstinence in patients with AUDs, and the preliminary findings demonstrate probable good outcomes. \[21\].~* It consists of a trained Nurse delivering three individual sessions with the patient over a span of two to three days (15 to 20 mins each) during their period of admission in the ward and one session with the family members.
Study: NCT04772989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB308
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB308
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB308
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB308
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB308
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB308
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB308
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB308
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered IV as specified in the treatment arm
Study: NCT04678843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Family-Based Treatment
Description: Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
Study: NCT05198856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Combined With Chemotherapy and Monotherapy
Description: Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions.
Study: NCT05807971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-063
Description: 12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
Study: NCT04772989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered IV as specified in the treatment arm
Study: NCT05303129

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )
Study: NCT05758402

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine practice group
Description: Routine practice group

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EARP group
Description: EARP group
Study: NCT06085716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention
Description: Participants in the PI group will complete the educational sessions only.
Study: NCT05807971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-063
Description: 12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-063
Description: 12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsule to the drug without the active ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsule to the drug without the active ingredient.
Study: NCT06347367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 (exercise and self-manual approaches targeting only the diaphragm muscles)
Description: Both groups will receive the patient education before treatment. Diaphragmatic stretching technique, pectoral muscle relaxation, diaphragmatic mobilisation, thoracic mobilisation and diaphragmatic breathing. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 (exercise and self-manual approaches targeting both diaphragm and core muscles)
Description: İn addition to Group 1, patients in group 2 will receive, abdominal massage, abdominal mobilisation, stabilisation exercises and pelvic floor muscle training. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
Study: NCT06085716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Placebo
Description: This group will only take placebo capsules every day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention+Placebo
Description: This group will take the placebo capsules every day, as well as completing the educational sessions.
Study: NCT05579847

Intervention type: OTHER
Intervention: mHealth Smart Phone Application
Description: The mHealth interactive application consists of educational intervention geared towards eligible patients who are receiving Nivolumab/ Pembro with Axitinib/Cabozantinib/Lenvatinib. These patients commonly experience immune-related side effects, higher rate of fatigue, high blood pressure, and palmar-plantar erythrodysesthesia. The educational intervention will consist of multiple modules covering relevant information on treatment and adverse events and provided over a six-week period through an mHealth platform. This educational intervention includes a patient-friendly algorithm for early detection and management of the most common adverse events in patients with advanced renal cell carcinoma receiving combination immunotherapy.

Intervention type: BEHAVIORAL
Intervention: eHEALS digital literacy test
Description: The eHEALS digital literacy test is an 8-item measure of eHealth literacy developed to measure the participants combined knowledge, comfort and perceived skills at finding, evaluating and applying electronic health information to health problems. The test is measured with a 5-point Likert scale with response options ranging from strongly disagree to strongly agree. Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy.

Intervention type: BEHAVIORAL
Intervention: Weekly Quiz
Description: Participants will take a weekly true/false quiz to assess knowledge of their diagnosis, expected outcome and treatment associated adverse effects at baseline and longitudinally. Each quiz will be administered at the beginning of the week before the weekly educational content is available, then the same quiz will be administered after the educational content is reviewed by the patient. Each quiz will be scored based on the number of correct answers.
Study: NCT06300099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone as adjunct to serratus anterior plane block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine as adjunct to serratus anterior plane block.
Study: NCT05194345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism Eats nutrition intervention
Description: The Autism Eats intervention group will spend about 8.5 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, and a 60-minute exit interview). The Autism Eats intervention group EI provider will spend about 12 hours over 5 months (two 90-minutes training sessions, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, 10-minute fidelity checklist completion after each session, and a 60-minute exit interview).